Literature DB >> 7866205

New treatments for multiple sclerosis.

W I McDonald.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7866205      PMCID： PMC2548759          DOI： 10.1136/bmj.310.6976.345

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs.

Authors:  J J Nauta; A J Thompson; F Barkhof; D H Miller
Journal:  J Neurol Sci       Date:  1994-03       Impact factor: 3.181

2.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Authors:  D W Paty; D K Li
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

3.  Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.

Authors:  T Moreau; J Thorpe; D Miller; I Moseley; G Hale; H Waldmann; D Clayton; M Wing; N Scolding; A Compston
Journal:  Lancet       Date:  1994-07-30       Impact factor: 79.321

4.  Cladribine in treatment of chronic progressive multiple sclerosis.

Authors:  J C Sipe; J S Romine; J A Koziol; R McMillan; J Zyroff; E Beutler
Journal:  Lancet       Date:  1994-07-02       Impact factor: 79.321
  4 in total
  5 in total

1.  Evaluating neurological outcome measures: the bare essentials.

Authors:  J C Hobart; D L Lamping; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

2.  A purchaser experience of managing new expensive drugs: interferon beta.

Authors:  E Rous; A Coppel; J Haworth; S Noyce
Journal:  BMJ       Date:  1996-11-09

3.  Telling your patient he/she has multiple sclerosis.

Authors:  H L Ford; M H Johnson
Journal:  Postgrad Med J       Date:  1995-08       Impact factor: 2.401

4.  Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.

Authors:  Kuriko Kagitani-Shimono; Ikuko Mohri; Yasushi Fujitani; Kinuko Suzuki; Keiichi Ozono; Yoshihiro Urade; Masako Taniike
Journal:  J Neuroinflammation       Date:  2005-04-06       Impact factor: 8.322

5.  Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis.

Authors:  K P Wandinger; K Wessel; P Neustock; A Siekhaus; H Kirchner
Journal:  J Neurol Sci       Date:  1997-07       Impact factor: 3.181
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.